170 related articles for article (PubMed ID: 11248162)
1. From the molecule to the clinic--inhibiting HER2 to treat breast cancer.
Eisenhauer EA
N Engl J Med; 2001 Mar; 344(11):841-2. PubMed ID: 11248162
[No Abstract] [Full Text] [Related]
2. Trastuzumab and breast cancer.
Palmieri C; Powles T; Vigushin D
N Engl J Med; 2001 Sep; 345(13):996-7. PubMed ID: 11575297
[No Abstract] [Full Text] [Related]
3. Trastuzumab/docetaxel-induced nail dystrophy.
Alexandrescu DT; Vaillant J; Wiernik PH
Int J Dermatol; 2006 Nov; 45(11):1334-6. PubMed ID: 17076719
[No Abstract] [Full Text] [Related]
4. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
[No Abstract] [Full Text] [Related]
6. ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).
Clin Adv Hematol Oncol; 2003 Apr; 1(4):237. PubMed ID: 16224413
[No Abstract] [Full Text] [Related]
7. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
8. [Trastuzumab for treatment of advanced breast cancers].
Watanabe T; Shimizu C; Katsumata N; Saijo N
Nihon Rinsho; 2000 Apr; 58 Suppl():340-4. PubMed ID: 11026016
[No Abstract] [Full Text] [Related]
9. Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
Oncology (Williston Park); 2005 Jun; 19(7):851, 862. PubMed ID: 16053034
[No Abstract] [Full Text] [Related]
10. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
11. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
Ficorella C
Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
[No Abstract] [Full Text] [Related]
12. Trastuzumab and breast cancer.
Behr TM; Béhé M; Wörmann B
N Engl J Med; 2001 Sep; 345(13):995-6. PubMed ID: 11575295
[No Abstract] [Full Text] [Related]
13. HER2-positive breast cancer: current treatment strategies.
Perez EA; Baweja M
Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
[No Abstract] [Full Text] [Related]
14. New developments in adjuvant therapy for breast cancer.
Sledge GW
Clin Adv Hematol Oncol; 2005 Sep; 3(9):688-90. PubMed ID: 16224442
[No Abstract] [Full Text] [Related]
15. Herceptin: help for advanced breast cancer.
Runowicz CD
Health News; 2001 May; 7(5):4. PubMed ID: 11851153
[No Abstract] [Full Text] [Related]
16. Cardiotoxicity concerns prompt data review in breast cancer trial.
Friedrich MJ
J Natl Cancer Inst; 2002 May; 94(9):650-1. PubMed ID: 11983752
[No Abstract] [Full Text] [Related]
17. Expanded use of Herceptin.
FDA Consum; 2007; 41(2):4-5. PubMed ID: 17590893
[No Abstract] [Full Text] [Related]
18. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
19. Blocking breast cancer relapses.
Johns Hopkins Med Lett Health After 50; 2006 Feb; 17(12):1-2. PubMed ID: 17115471
[No Abstract] [Full Text] [Related]
20. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
